Skip to main content

Table 2 Clinical–epidemiological characteristics of the population with CKD according to the PLR level

From: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as risk factors for mortality in Peruvian adults with chronic kidney disease

Characteristics PLR p value
High (n = 28) Normal (n = 314)
Age (years)* 72.6 (14.1) 78.8 (11.6)  < 0.01
Sex**
Female 8 (28.6) 119 (37.9) 0.33
Male 20 (71.4) 195 (62.1)  
Hypertension** 0.37
Yes 16 (57.1) 206 (65.6)  
No 12 (42.9) 108 (34.4)  
Diabetes** 0.48
Yes 10 (35.7) 92 (29.3)  
No 28 (64.3) 222 (70.7)  
CKD stage**
1–2 2 (7.2) 20 (6.4) 0.62
3a–3b 26 (92.8) 284 (90.4)  
4–5 0 (0.0) 10 (3.2)  
Laboratory profile
Serum creatinine (mg/dL)* 1.4 (0.3) 1.4 (0.5) 0.94
eGFR (ml/min/1.73 m2)* 49.0 (11.1) 47.2 (10.5) 0.40
Glucose (mg/dL)*** 88.5 (77–112) 90 (83–103) 0.47
Total protein (g/dL)* 7.1 (0.7) 7.2 (0.6) 0.15
Albumin (g/dL)* 4.0 (0.5) 4.1 (0.4) 0.06
AST (U/L)*** 19 (18–25) 23 (19–28) 0.02
ALT (U/L)*** 16 (12–24) 18 (13–24) 0.47
Total bilirubin (mg/dL)*** 0.5 (0.44–0.70) 0.6 (0.45–0.79) 0.46
Alkaline phosphatase (U/L)*** 117 (91–146) 100 (81.5–126) 0.08
Globulin (g/dL)* 3.1 (0.5) 3.1 (0.8) 0.73
Hemoglobin (g/dL)* 11.2 (1.9) 12.2 (1.6)  < 0.01
Neutrophils (K/uL)* 4.53 (1.6) 3.89 (1.5) 0.03
  1. eGFR estimated glomerular filtration rate, CKD chronic kidney disease, AST aspartate aminotransferase, ALT alanine aminotransferase, PLR platelet–lymphocyte ratio
  2. *Mean (standard deviation)
  3. **Frequency (percent)
  4. ***Median (p25–p75)